Clinical trials: Coagulation
Hemophilia A
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A
This study is to test whether the study drug (OBI-1) is safe and effective for the treatment of serious bleeding episodes in people with congenital hemophilia A.
- Trial name
- NCT01434511
- Testing
- OBI-1
- Where
- 3 sites in United States, South Africa and 1 more
- Volunteers
- 1 people
- Sponsor
- Baxalta now part of Shire
Essential Thrombocythemia
Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET
This is a multicenter, randomized, open-label Phase 2 clinical study. It is aimed to enroll 27 essential thrombocytopenia (ET) patients who are resistant to or intolerant of hydroxyurea(HU).
- Trial name
- NCT06552429
- Testing
- Peginterferon α-2b injection
- Where
- 8 sites in China
- Volunteers
- 27 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Radiofrequency Can be Used to Treat Splenic Trauma Because of Its Excellent Coagulation Hemostasis
RF-assisted Splenic Preservation VS Conventional Treatment of Blunt Splenic Injury.
Radiofrequency (RF) can be used to treat splenic trauma because of its excellent coagulation hemostasis. This study aimed to compare the efficacy of RF-assisted spleen-preserving surgery with that of conventional…
- Trial name
- NCT03890328
- Testing
- radiofrequency ablation
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Southwest Hospital, China
Hemophilia a, Hemophilia B
The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial
The purpose of the study is to evaluate the efficacy, safety, tolerability and pharmacokinetic (PK) profile of prophylactic SerpinPC in participants with hemophilia
- Conditions
- Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor
- Trial name
- PRESent-6 (NCT06568302)
- Testing
- SerpinPC
- Where
- 2 sites in Georgia, Moldova
- Volunteers
- 15 people
- Sponsor
- ApcinteX Ltd
Hemophilia A
Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A
This study is to generate qualitative data to evaluate the impact of frequency of FVIII infusions on patients' satisfaction with treatment and their quality of life.
- Trial name
- NCT02971930
- Testing
- BAY94-9027
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Bayer
Von Willebrand Disease
Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease
Multicenter, prospective, non-controlled study in a pediatric cohort (<6 years-old) with severe (type 2 or 3) hereditary Von Willebrand Disease (VWD).
- Trial name
- NCT02472665
- Testing
- plasma-derived FVIII/VWF concentrate
- Where
- 4 sites in Spain
- Sponsor
- Grifols Therapeutics LLC
Immune Thrombocytopenia
A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）
The project was undertaking by Qilu Hospital, Shandong University and other several well-known hospitals in China. In order to report the efficacy and safety of Rituximab in different frequencies for the treatment of adults with…
- Trial name
- NCT02137681
- Testing
- Rituximab
- Where
- China
- Sponsor
- Shandong University
Severe Hemophilia A
Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform
This study will evaluate if Eloctate is superior to Emicizumab in reducing inhibitors in children with severe hemophilia when given before the first bleed (preemptive) and continued weekly to prevent bleeds (prophylaxis); and…
- Trial name
- INHIBIT (NCT02196207)
- Testing
- Eloctate Prophylaxis, Emicizumab Prophylaxis, Eloctate ITI plus Emicizumab
- Where
- United States
- Sponsor
- Margaret Ragni
Hemophilia A, Hemophilia A, Severe
Hemophilia A Research Program
This study longitudinally observes the intergenerational (mother-child) continuum in hemophilia A from pregnancy through early childhood.
- Conditions
- Hemophilia A, Hemophilia A, Severe, Factor VIII (FVIII), FVIII Deficiency
- Trial name
- HARP (NCT07414511)
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Washington
Immune Thrombocytopenia (ITP)
Clinical Study of CHT105 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
Primary Objective: To evaluate the safety and efficacy of CHT105 Injection in subjects with relapsed/refractory autoimmune diseases.
- Trial name
- NCT07811622
- Testing
- CHT105
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Nanjing Miracle Biotechnology Co., Ltd.
Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Open Label Extension Study of AMG 531 in Japanese Subjects With ITP
The purpose of this study is to assess the safety and efficacy of long term dosing of AMG 531 in thrombocytopenic Japanese subjects with ITP.
- Trial name
- NCT00440037
- Testing
- AMG 531
- Where
- 13 sites in Japan
- Volunteers
- 44 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Pneumonia, Lipopolysaccharides
Effect of Intrapulmonary Recombinant Human Activated Protein C (APC) on Coagulation and Inflammation After Lipopolysaccharide (LPS)
Recombinant human Activated Protein C (rhAPC) has been shown to reduce the mortality of patients with severe sepsis. The biological effects of APC are pleiotropic, and can be roughly divided in anticoagulant and cytoprotective…
- Trial name
- NCT00943267
- Testing
- Drotrecogin alpha, Saline (NaCl 0.9%), Endotoxin
- Where
- Netherlands
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Septic Shock, Coagulopathy
Study Assessing Efficacy of Plasmatherapy in Septic Shock-induced Coagulopathy: Feasibility Study
No randomized controlled trial (RCT) has investigated the effect of prophylactic fresh frozen plasma (FFP) transfusion in septic or critically ill patients with coagulation abnormalities.
- Conditions
- Septic Shock, Coagulopathy, Disseminated Intravascular Coagulation
- Trial name
- PlasmaFaisa (NCT04580563)
- Testing
- OctaplasLG®, 0.9% NaCl
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Strasbourg, France
Myelofibrosis, Essential Thrombocythemia
CEP-701 (Lestaurtinib) in Myelofibrosis
Myelofibrosis is the gradual replacement of bone marrow (place where most new blood cells are produced) by fibrous tissue which reduces the body's ability to produce new blood cells and results in the development of chronic…
- Conditions
- Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera
- Trial name
- NCT00668421
- Testing
- CEP-701 (Lestaurtinib)
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ronald Hoffman
Hemophilia a and B
KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors
The goal of this clinical trial is to evaluate the safety and efficacy of KN057 in adult patients with severe Hemophilia A (coagulation factor FVIII activity <1%) or moderate-to-severe Hemophilia B (FIX activity ≤2%).
- Trial name
- NCT06747416
- Testing
- KN057
- Volunteers
- 24 people
- Sponsor
- Suzhou Alphamab Co., Ltd.
Obstetric Labor Complications, Hemorrhage
Coagulation Factor Changes Associated With Postpartum Hysterectomies
The purpose of this study is to examine components of the coagulation system in women undergoing postpartum hysterectomy and to compare laboratory parameters of coagulation in these women to women at increased risk for a…
- Conditions
- Obstetric Labor Complications, Hemorrhage, Complications; Cesarean Section
- Trial name
- NCT00456547
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Polycythemia Vera, Essential Thrombocythemia
Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)
The incidence of secondary cancer (SC) in patients with myeloproliferative neoplasms (MPN) is high and comparable to that of thrombosis.
- Conditions
- Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis
- Trial name
- MPN-K (NCT03745378)
- Testing
- JAK2V617F mutation
- Where
- 30 sites in Czechia, Germany and 4 more
- Volunteers
- 1,881 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Myeloproliferative Neoplasm
Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms
Thrombosis is the main cause of morbidity and mortality in patients with myeloproliferative neoplasms (MPN). However, the pathogenesis of thrombosis in MPN is still largely elusive.
- Trial name
- MPN-BIOCLOT (NCT04177576)
- Testing
- 2 additional tubes of blood
- Where
- 24 sites in France
- Volunteers
- 397 people
- Sponsor
- University Hospital, Bordeaux
Corticosteroids Adverse Reaction
Impact of Antenatal Steroids on Coagulation.
Aim of the research : 1- Detection of the presence or absence of any effect of antenatal corticosteroid administration on coagulopathy, fibrinolysis, and other haematological markers.
- Trial name
- NCT06312852
- Volunteers
- 45 people
- Sponsor
- Assiut University
Hemophilia A
Clot Formation and Clot Stability in Patients With Severe Haemophilia A
In the present study we are examining the clot formation and clot stability in patients with severe haemophilia A after they receive recombinat factor VIII and after addition of tranexamic acid.
- Trial name
- NCT00279578
- Testing
- ReFacto (Recombinant factor VIII) and Tranexamic acid
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- University of Aarhus
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.